Pica Eating Disorder Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB511247635

Publication Date:

November 27, 2024

Pages:

112

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Pica is an eating disorder in which people eat nonnutritive substances which are not typically thought as food such as paper, cloth, soap, hair, wool, soil, chalk, string, talcum powder, gum, paint, metal, pebbles, charcoal, ash, clay, starch, or ice. This can lead to intoxication in children which may result in impairment of both mental and physical development. Pica eating disorder can occur in any age group. There is no such kind of laboratory tests for pica instead the diagnosis can be done clinically. Iron deficiency anemia and malnutrition are the most common cause of the pica. There are various pica eating disorder treatment options available by using dietary supplements, different therapies are also available like psychotic therapy, cognitive behavioral approaches, nutritional counselling etc. Diagnosis of pica can be accompanied by the test for anemia as pica can occur in people who are malnourished. A lead level should be check-in children who have eaten any paint or objects covered in paint for lead poisoning. Pica eating disorder can lead to surgical emergencies due to obstructions in the intestine and parasitosis. Pica eating disorder often occurs with the mental health disorders which are associated with impaired functioning and can be seen in pregnant women. The pica eating disorder treatment may vary from patient to patient and may have psychosocial, environmental and family guidance approaches. Iron deficiency can be treated by iron supplements.
The global market for Pica Eating Disorder Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Pica Eating Disorder Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pica Eating Disorder Treatment by region & country, by Type, and by Application.
The Pica Eating Disorder Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pica Eating Disorder Treatment.
Market Segmentation
By Company
Novartis International AG
GlaxoSmithKline plc.
Merck KGaA
Sun Pharmaceutical Industries Limited
Glenmark Pharmaceutical
Torrent Pharmaceuticals Ltd.
Micro Labs Limited
FDC Limited
Emcure Pharmaceuticals
Mankind Pharma
Segment by Type:
Dietary Supplements
Antipsychotic Drugs
Antidepressants
Mood Stabilizers
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Mail Order Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pica Eating Disorder Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pica Eating Disorder Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pica Eating Disorder Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Pica Eating Disorder Treatment Product Introduction
1.2 Global Pica Eating Disorder Treatment Market Size Forecast
1.3 Pica Eating Disorder Treatment Market Trends & Drivers
1.3.1 Pica Eating Disorder Treatment Industry Trends
1.3.2 Pica Eating Disorder Treatment Market Drivers & Opportunity
1.3.3 Pica Eating Disorder Treatment Market Challenges
1.3.4 Pica Eating Disorder Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Pica Eating Disorder Treatment Players Revenue Ranking (2023)
2.2 Global Pica Eating Disorder Treatment Revenue by Company (2019-2024)
2.3 Key Companies Pica Eating Disorder Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Pica Eating Disorder Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Pica Eating Disorder Treatment
2.6 Pica Eating Disorder Treatment Market Competitive Analysis
2.6.1 Pica Eating Disorder Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Pica Eating Disorder Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pica Eating Disorder Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Dietary Supplements
3.1.2 Antipsychotic Drugs
3.1.3 Antidepressants
3.1.4 Mood Stabilizers
3.2 Global Pica Eating Disorder Treatment Sales Value by Type
3.2.1 Global Pica Eating Disorder Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Pica Eating Disorder Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Pica Eating Disorder Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital Pharmacies
4.1.2 Retail Pharmacies
4.1.3 Drug Stores
4.1.4 Mail Order Pharmacies
4.2 Global Pica Eating Disorder Treatment Sales Value by Application
4.2.1 Global Pica Eating Disorder Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Pica Eating Disorder Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Pica Eating Disorder Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Pica Eating Disorder Treatment Sales Value by Region
5.1.1 Global Pica Eating Disorder Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Pica Eating Disorder Treatment Sales Value by Region (2019-2024)
5.1.3 Global Pica Eating Disorder Treatment Sales Value by Region (2025-2030)
5.1.4 Global Pica Eating Disorder Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Pica Eating Disorder Treatment Sales Value, 2019-2030
5.2.2 North America Pica Eating Disorder Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Pica Eating Disorder Treatment Sales Value, 2019-2030
5.3.2 Europe Pica Eating Disorder Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Pica Eating Disorder Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Pica Eating Disorder Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Pica Eating Disorder Treatment Sales Value, 2019-2030
5.5.2 South America Pica Eating Disorder Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Pica Eating Disorder Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Pica Eating Disorder Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Pica Eating Disorder Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Pica Eating Disorder Treatment Sales Value
6.3 United States
6.3.1 United States Pica Eating Disorder Treatment Sales Value, 2019-2030
6.3.2 United States Pica Eating Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Pica Eating Disorder Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Pica Eating Disorder Treatment Sales Value, 2019-2030
6.4.2 Europe Pica Eating Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Pica Eating Disorder Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Pica Eating Disorder Treatment Sales Value, 2019-2030
6.5.2 China Pica Eating Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Pica Eating Disorder Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Pica Eating Disorder Treatment Sales Value, 2019-2030
6.6.2 Japan Pica Eating Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Pica Eating Disorder Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Pica Eating Disorder Treatment Sales Value, 2019-2030
6.7.2 South Korea Pica Eating Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Pica Eating Disorder Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Pica Eating Disorder Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Pica Eating Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Pica Eating Disorder Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Pica Eating Disorder Treatment Sales Value, 2019-2030
6.9.2 India Pica Eating Disorder Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Pica Eating Disorder Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Novartis International AG
7.1.1 Novartis International AG Profile
7.1.2 Novartis International AG Main Business
7.1.3 Novartis International AG Pica Eating Disorder Treatment Products, Services and Solutions
7.1.4 Novartis International AG Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Novartis International AG Recent Developments
7.2 GlaxoSmithKline plc.
7.2.1 GlaxoSmithKline plc. Profile
7.2.2 GlaxoSmithKline plc. Main Business
7.2.3 GlaxoSmithKline plc. Pica Eating Disorder Treatment Products, Services and Solutions
7.2.4 GlaxoSmithKline plc. Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 GlaxoSmithKline plc. Recent Developments
7.3 Merck KGaA
7.3.1 Merck KGaA Profile
7.3.2 Merck KGaA Main Business
7.3.3 Merck KGaA Pica Eating Disorder Treatment Products, Services and Solutions
7.3.4 Merck KGaA Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Sun Pharmaceutical Industries Limited Recent Developments
7.4 Sun Pharmaceutical Industries Limited
7.4.1 Sun Pharmaceutical Industries Limited Profile
7.4.2 Sun Pharmaceutical Industries Limited Main Business
7.4.3 Sun Pharmaceutical Industries Limited Pica Eating Disorder Treatment Products, Services and Solutions
7.4.4 Sun Pharmaceutical Industries Limited Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Sun Pharmaceutical Industries Limited Recent Developments
7.5 Glenmark Pharmaceutical
7.5.1 Glenmark Pharmaceutical Profile
7.5.2 Glenmark Pharmaceutical Main Business
7.5.3 Glenmark Pharmaceutical Pica Eating Disorder Treatment Products, Services and Solutions
7.5.4 Glenmark Pharmaceutical Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Glenmark Pharmaceutical Recent Developments
7.6 Torrent Pharmaceuticals Ltd.
7.6.1 Torrent Pharmaceuticals Ltd. Profile
7.6.2 Torrent Pharmaceuticals Ltd. Main Business
7.6.3 Torrent Pharmaceuticals Ltd. Pica Eating Disorder Treatment Products, Services and Solutions
7.6.4 Torrent Pharmaceuticals Ltd. Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Torrent Pharmaceuticals Ltd. Recent Developments
7.7 Micro Labs Limited
7.7.1 Micro Labs Limited Profile
7.7.2 Micro Labs Limited Main Business
7.7.3 Micro Labs Limited Pica Eating Disorder Treatment Products, Services and Solutions
7.7.4 Micro Labs Limited Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Micro Labs Limited Recent Developments
7.8 FDC Limited
7.8.1 FDC Limited Profile
7.8.2 FDC Limited Main Business
7.8.3 FDC Limited Pica Eating Disorder Treatment Products, Services and Solutions
7.8.4 FDC Limited Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 FDC Limited Recent Developments
7.9 Emcure Pharmaceuticals
7.9.1 Emcure Pharmaceuticals Profile
7.9.2 Emcure Pharmaceuticals Main Business
7.9.3 Emcure Pharmaceuticals Pica Eating Disorder Treatment Products, Services and Solutions
7.9.4 Emcure Pharmaceuticals Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.9.5 Emcure Pharmaceuticals Recent Developments
7.10 Mankind Pharma
7.10.1 Mankind Pharma Profile
7.10.2 Mankind Pharma Main Business
7.10.3 Mankind Pharma Pica Eating Disorder Treatment Products, Services and Solutions
7.10.4 Mankind Pharma Pica Eating Disorder Treatment Revenue (US$ Million) & (2019-2024)
7.10.5 Mankind Pharma Recent Developments
8 Industry Chain Analysis
8.1 Pica Eating Disorder Treatment Industrial Chain
8.2 Pica Eating Disorder Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Pica Eating Disorder Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Pica Eating Disorder Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Novartis International AG
GlaxoSmithKline plc.
Merck KGaA
Sun Pharmaceutical Industries Limited
Glenmark Pharmaceutical
Torrent Pharmaceuticals Ltd.
Micro Labs Limited
FDC Limited
Emcure Pharmaceuticals
Mankind Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂